Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis.

Daniel G Fernández-Ávila,Wilson Bautista-Molano,María Lorena Brance, María Gabriela Ávila Pedretti, Rubén Burgos Vargas, José Francisco Díaz Coto, Luis Arturo Gutiérrez, Marwin Gutiérrez, Enrique Giraldo Ho, Sebastián Eduardo Ibáñez Vodnizza, Edwin Jáuregui,Vanessa Ocampo,Penélope Esther Palominos, Daniel Ruben Palleiro Rivero,Guillermo Andrés Quiceno,Fernando Andrés Sommerfleck,Luis Enrique Vega Espinoza, Oscar Vega Hinojosa,Claudia Vera Barrezueta, Inés Corbacho,Vanesa Laura Cosentino, Annelise Goecke Sariego,Gustavo Gomes Resende, Lina María Saldarriaga-Rivera, Cesar Francisco Pacheco Tena, Gustavo Citera, Carlos Lozada,Roberto Ranza,Percival D Sampaio-Barros, Emilce Schneeberger,Enrique R Soriano, on behalf of the Pan American League of Associations for Rheumatology (PANLAR)

The Journal of rheumatology(2024)

引用 0|浏览5
暂无评分
摘要
OBJECTIVE:Psoriatic arthritis (PsA) is chronic disease that compromises multiple domains and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective was to generate evidence-based recommendations on the management of PsA in Pan American League of Associations for Rheumatology (PANLAR) countries. METHODS:We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach to adapt the 2019 recommendations of the European Alliance of Associations for Rheumatology. A working group consisting of rheumatologists from various countries in Latin America identified relevant topics for the treatment of PsA in the region. The methodology team updated the evidence and synthesized the information used to generate the final recommendations. These were then discussed and defined by a panel of 31 rheumatologists from 15 countries. RESULTS:Theses guidelines report 15 recommendations addressing therapeutic targets, use of antiinflammatory agents and corticosteroids, treatment with disease-modifying antirheumatic drugs (conventional synthetic, biologic, and targeted synthetic), therapeutic failure, optimization of biologic therapy, nonpharmacological interventions, assessment tools, and follow-up of patients with PsA. CONCLUSION:Here we present a set of recommendations to guide decision making in the treatment of PsA in Latin America, based on the best evidence available, considering resources, medical expertise, and the patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, healthcare settings in each country, and a tailored evaluation of patients.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要